Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:PARNAXLAB

PARNAX LAB LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹109.50
at close · 30 Oct 2026
▼ 0.19 (-0.17%)
ThemesArtificial Intelligence· mentionCybersecurity· mention

Latest filings

  1. RTA Confirmation Certificate for Q2 FY27 Dematerialisation - Parnax Lab · Compliance
  2. Parnax Lab AGM 2026: All 4 resolutions passed unanimously · Board & Shareholder Meetings
  3. Parnax Lab appoints Ladha Singhal & Associates as statutory auditor · Management Changes
All filings ↓
Ask Nexa about PARNAX LAB LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹249 Cr over the trailing twelve months.

Market Cap
₹126 Cr
P / E (TTM)
10.7×
EV / EBITDA
7.3×
Div Yield
—
Growth
22.7%▲
Revenue 5y CAGR
PAT — · EBITDA +22.3%
Quality
18.2%▲
ROCE (5y median)
ROE 13.9% (5y median) · margin 11.0%
Leverage
0.78·
Debt / Equity · moderate
Net debt ₹74 Cr
Revenue FY21→FY26
2.8×▲
Margin +5.1 pts
₹90 Cr → ₹249 Cr
Cash conversion
1.73×▲
Operating cash ÷ profit · 5 yrs
₹86 Cr on ₹50 Cr
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#21/160
P/B#37/163
ROCE#69/182
ROE#52/165
Debt / Equity#149/166
EBITDA margin#125/177
Revenue growth#31/161
Profit growth#115/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 23% a year over 5 years
Profit grew in every one of the last 5 years
Returns on capital 18.2% (5-year median)
#69 of 182 in Pharmaceuticals on the latest reported figures · up from 9.6% in FY21
Over 5 years it reported ₹50 Cr of profit and ₹86 Cr of operating cash — 1.73×
Profit is converting into cash
Concerns
Carries more debt than its peers — 0.78× equity
higher than 90% of its 166 Pharmaceuticals peers

Charts

How has the market priced it — with filings on the timeline?

PARNAXLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from PARNAX LAB LTD.'s filed financials and exchange disclosures

What does PARNAX LAB LTD. do?

PARNAX LAB LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol PARNAXLAB.

Is PARNAX LAB LTD. profitable?

Yes. Over the trailing twelve months PARNAX LAB LTD. reported a net profit of ₹12 Cr on revenue of ₹249 Cr.

Does PARNAX LAB LTD. pay a dividend?

Not in the latest reported year — PARNAX LAB LTD.'s dividend payout for FY26 was nil.

Is PARNAX LAB LTD. debt-free?

No. It reported borrowings of ₹75 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹74 Cr after cash. Debt stands at 0.78× equity. That is higher than 90% of its 166 Pharmaceuticals peers.

Is PARNAX LAB LTD. expensive compared with its peers?

On trailing P/E, PARNAX LAB LTD. ranks 21 of 160 in Pharmaceuticals — cheaper than 87% of them, against an industry median of 29.9×. This is a position, not a valuation judgement.

Where can I track PARNAX LAB LTD.'s announcements?

Every NSE and BSE filing by PARNAX LAB LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.